Mir müssen die zu erwartenden Umsätze noch hochrechnen, um uns ein Bild machen zu können.
|
|
Aeterna Zentaris (NASDAQ:AEZS) is up 53% - after hours - on robust volume...
Leider muss ich euch morgen alleine lassen.
Growth Opportunity
There are more than 70,000 AGHD patients in the US and EU combined. Currently, IGF-1 tests may cost $200 at some clinics. There are other such STIM tests available, although none are specifically FDA-approved. If Macrilen is approved as a repeatable test with adequate sensitivity and specificity, it will be looking at a diversified market worth around $14 million per year. The company though claims around $30-$50mn in the US alone. This claim is made from an estimate of 40,000 tests per year and a cost for the test of approximately $1200 per test. In a very bullish scenario, this may be possible due to the drug’s orphan status, the small size of the prescriber locations, and the best-in-class profile of the test.
http://seekingalpha.com/article/...-zentaris-upside-valuation-company
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |